hrs Search Results


93
Addgene inc rfp
Rfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/pCS2+HRS-RFP+(Plasmid+%2329685)/10__1523_slash_jneurosci__2811___18__2019-86-42-46
Average 93 stars, based on 1 article reviews
rfp - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
ABclonal Biotechnology hgs
Hgs, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/HGS+Rabbit+pAb/pmc11959923-91-44-45
Average 94 stars, based on 1 article reviews
hgs - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

91
Proteintech srsf5
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Srsf5, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/SFRS5+Antibody/pm37563801-57-22-23
Average 91 stars, based on 1 article reviews
srsf5 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology proteins
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Proteins, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/Hrs+Antibody/pmc12397353-329-5-9
Average 93 stars, based on 1 article reviews
proteins - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
Fortis Life Sciences anti hrs
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Anti Hrs, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/HRS+Antibody/pmc03442408-175-57-59
Average 92 stars, based on 1 article reviews
anti hrs - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc hrs
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Hrs, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/HRS+Rabbit+mAb/bio_rxiv__2021__01__25__428055-194-23-24
Average 95 stars, based on 1 article reviews
hrs - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Proteintech 10390 1 ap
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
10390 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/HGS+Antibody/pmc08567383-5-4-2
Average 93 stars, based on 1 article reviews
10390 1 ap - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
OriGene srsf5 gfp plasmid
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Srsf5 Gfp Plasmid, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/SFRS5+(SRSF5)+(NM_006925)+Human+Tagged+ORF+Clone/pmc07835670-176-6-8
Average 90 stars, based on 1 article reviews
srsf5 gfp plasmid - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Addgene inc pkh116 keima yipf3 plasmid
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Pkh116 Keima Yipf3 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/pST39-Hrs-STAM1+core+(Plasmid+%2321497)/bio_rxiv__2025__09__04__674289-287-8-11
Average 93 stars, based on 1 article reviews
pkh116 keima yipf3 plasmid - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Proteintech anti mmp9
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Anti Mmp9, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/HARS+Antibody/pmc09173650-94-15-18
Average 93 stars, based on 1 article reviews
anti mmp9 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
OriGene pcmv6 myc ddk hgs expression plasmid
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Pcmv6 Myc Ddk Hgs Expression Plasmid, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/HGS+(NM_004712)+Human+Tagged+ORF+Clone/pmc04911576-191-10-16
Average 90 stars, based on 1 article reviews
pcmv6 myc ddk hgs expression plasmid - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
OriGene flag tagged wt hgs
Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or <t>SRSF5</t> binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.
Flag Tagged Wt Hgs, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hrs/HGS+(NM_004712)+Human+Tagged+ORF+Clone+Lentiviral+Particle/pmc08915906__pnas__2107453119__sapp-8-0-7
Average 90 stars, based on 1 article reviews
flag tagged wt hgs - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or SRSF5 binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.

Journal: Journal of dental research

Article Title: Mutations Causing X-Linked Amelogenesis Imperfecta Alter miRNA Formation from Amelogenin Exon4.

doi: 10.1177/00220345231180572

Figure Lengend Snippet: Figure 1. Alternative splicing and exon splicing enhancers (ESEs). (A) Models for skipping or inclusion of an alternative exon. (Upper) In most cases, an alternative exon (E2) is skipped. It is because of the strong Ser/Arg-rich RNA splicing factor (SRSF) binding site on the conserved exons (E1 or E3). (Lower) The alternative exon is included only when the binding of the SRSF to the ESE on the conserved exon is disrupted or the binding of an SRSF to the weak ESE on the alternative exon is enhanced. (B) X-linked amelogenesis imperfecta causative mutations on exon4 and exon5 occur in putative ESE sequences for SRSF2 or SRSF5 binding, respectively. The mutation in exon4 is predicted to enhance SFSR2 binding (Cho et al. 2014), and the 4 mutations in exon5 are predicted to disable SRSF5 binding. Both of them, in turn, are expected to suppress exon4 splicing.

Article Snippet: Cy5.5-labeled RNA oligonucleotide probes for exon4 (200 ng) and exon5 (150 ng) (Dharmacon) were incubated with recombinant human SRSF2 (Creative Biomart) and SRSF5 (Proteintech) (5 fmol each) using the Odyssey Infrared EMSA Kit (Licor).

Techniques: Alternative Splicing, Binding Assay, Mutagenesis

Figure 4. Ser/Arg-rich RNA splicing factors (SRSF) 2 and SRSF5 to regulate exon4 splicing. (A) Electrophoretic mobility shift assay (EMSA) of exon4 RNA and SRSF2. The presence of super-shifted bands by mixing exon4 wild-type (WT) RNA and SRSF2 and the disappearance of the super shift by further adding a competitor confirm that SRSF2 specifically bounds exon4 WT via 3 exon splicing enhancer (ESE) forming complexes. Possible complex formations with SRSF2 and RNA are shown in Appendix Figure 3. With c.120T>C mutation, complex 2 and 3 portions increase. (B) EMSA of exon5 RNA and SRSF5. The presence of super-shifted bands by mixing exon5 WT RNA and SRSF5 and the disappearance of the super shift by adding competitor confirm that SRSF5 bounds exon5 WT via 2 ESE forming complexes 1 and 2. Possible complex formations with SRSF5 and RNA are shown in Appendix Figure 4. With c.155C>G mutation, complex 1 shifted back to the free RNA. With c.155del mutation, complex 1 super-shifted to complex 2. No change in complex formation with c.152C>T mutation. (C) Srsf2 and Srsf5 expressions in mouse enamel organs at P0 (presecretory stage) and P5 (secretory stage). Data are plotted on the graph, and bars are shown as ± SD. Total animal number = 8. Statistical analysis was done with an independent Student’s t test. **P < 0.01. ***P < 0.001. (D) Immunostaining of SRSF2 and SRSF5 on presecretory and secretory ameloblasts (Am) of mandibular incisor. The immunoreaction is in red. The counterstaining is in light green. Bar: 20 µm. (E) Proposed process for exon4 splicing and formation of mature miR-exon4. When bound to ESEs, the SRSFs recruit small nuclear RNAs (U1–6) to form the spliceosome complex (Auyeung et al. 2013) and define exons or introns. When SRSF5 binds to exon5 in pre-mRNA, exon4 is skipped. The spliced introns and exon4 are further processed to be a mature miRNA. When the binding of SRSF5 to exon5 is weakened, or the binding of SRSF2 to exon4 is enhanced, exon4 is included in mRNA.

Journal: Journal of dental research

Article Title: Mutations Causing X-Linked Amelogenesis Imperfecta Alter miRNA Formation from Amelogenin Exon4.

doi: 10.1177/00220345231180572

Figure Lengend Snippet: Figure 4. Ser/Arg-rich RNA splicing factors (SRSF) 2 and SRSF5 to regulate exon4 splicing. (A) Electrophoretic mobility shift assay (EMSA) of exon4 RNA and SRSF2. The presence of super-shifted bands by mixing exon4 wild-type (WT) RNA and SRSF2 and the disappearance of the super shift by further adding a competitor confirm that SRSF2 specifically bounds exon4 WT via 3 exon splicing enhancer (ESE) forming complexes. Possible complex formations with SRSF2 and RNA are shown in Appendix Figure 3. With c.120T>C mutation, complex 2 and 3 portions increase. (B) EMSA of exon5 RNA and SRSF5. The presence of super-shifted bands by mixing exon5 WT RNA and SRSF5 and the disappearance of the super shift by adding competitor confirm that SRSF5 bounds exon5 WT via 2 ESE forming complexes 1 and 2. Possible complex formations with SRSF5 and RNA are shown in Appendix Figure 4. With c.155C>G mutation, complex 1 shifted back to the free RNA. With c.155del mutation, complex 1 super-shifted to complex 2. No change in complex formation with c.152C>T mutation. (C) Srsf2 and Srsf5 expressions in mouse enamel organs at P0 (presecretory stage) and P5 (secretory stage). Data are plotted on the graph, and bars are shown as ± SD. Total animal number = 8. Statistical analysis was done with an independent Student’s t test. **P < 0.01. ***P < 0.001. (D) Immunostaining of SRSF2 and SRSF5 on presecretory and secretory ameloblasts (Am) of mandibular incisor. The immunoreaction is in red. The counterstaining is in light green. Bar: 20 µm. (E) Proposed process for exon4 splicing and formation of mature miR-exon4. When bound to ESEs, the SRSFs recruit small nuclear RNAs (U1–6) to form the spliceosome complex (Auyeung et al. 2013) and define exons or introns. When SRSF5 binds to exon5 in pre-mRNA, exon4 is skipped. The spliced introns and exon4 are further processed to be a mature miRNA. When the binding of SRSF5 to exon5 is weakened, or the binding of SRSF2 to exon4 is enhanced, exon4 is included in mRNA.

Article Snippet: Cy5.5-labeled RNA oligonucleotide probes for exon4 (200 ng) and exon5 (150 ng) (Dharmacon) were incubated with recombinant human SRSF2 (Creative Biomart) and SRSF5 (Proteintech) (5 fmol each) using the Odyssey Infrared EMSA Kit (Licor).

Techniques: Electrophoretic Mobility Shift Assay, Mutagenesis, Immunostaining, Binding Assay